Article: FDA grants 177Lu-PSMA-617 breakthrough designation for mCRPC

[GregHouston]

The FDA has granted a Breakthrough Therapy Designation to the targeted radioligand therapy 177Lu-PSMA-617 (LuPSMA) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).1

The designation, which will expedite the development and regulatory review of LuPSMA in this setting, is based on findings from the phase 3 VISION trial. In the study, adding LuPSMA to standard of care (SOC) led to a nearly 40% reduction in the risk of death versus SOC alone in patients with progressive PSMA-positive mCRPC.2

The findings, which were presented during the 2021 ASCO Annual Meeting, showed that at a median follow-up of 20.9 months, the addition of LuPSMA improved the median overall survival (OS) by 4 months over SOC alone (HR, 0.62). Adding the targeted radioligand therapy also led to a 5.3-month improvement in median radiographic progression-free survival (rPFS), translating to a 60% reduction in the risk of progression or death (HR, 0.40).

The open-label phase 3 VISION trial (NCT03511664) included 831 patients (1179 initially screened) with progressive PSMA-positive mCRPC who received at least 1 novel androgen axis drug (eg, enzalutamide [Xtandi] or abiraterone acetate [Zytiga]) and were previously treated with 1 to 2 taxane regimens.

PET imaging with 68Ga-PSMA-11 was used to determine PSMA positivity. Patient demographics and baseline characteristics were well balanced at baseline.

Patients were randomized in a 2:1 ratio to LuPSMA (7.4 GBq every 6 weeks x 6 cycles; n = 551) plus SOC or SOC alone (n = 280). Individual investigators determined the SOC; however, radium-223 (Xofigo) and cytotoxic chemotherapy were not allowed. The coprimary end points of the trial were OS and rPFS.

The median OS was 15.3 months in the LuPSMA arm versus 11.3 months in the SOC alone arm, translating to a 38% reduction in the risk of death (HR, 0.62; 95% CI, 0.52-0.74; P <.001).The rPFS was 8.7 versus 3.4 months, respectively (HR, 0.40; 99.2% CI, 0.29-0.57; P <.001).

There was also a statistically significant benefit favoring the LuPSMA arm for the key secondary endpoints of objective response rate (ORR), disease control rate (DCR), and time to first symptomatic skeletal event (SSE). The ORRs and DCRs were 29.8% versus 1.7% and 89.0% versus 66.7%, respectively. The median time to first SSE was 11.5 months in the LuPSMA group compared with 6.8 months in the control arm (HR, 0.50).

The safety analysis included 529 patients in the LuPSMA cohort and 205 patients in the control group. The investigators considered LuPSMA treatment to be well tolerated. The most common adverse events (AEs) across all grades occurring in the LuPSMA arm were fatigue (49.1% vs 29.3% in the control arm), bone marrow suppression (47.4% vs 17.6%, respectively), dry mouth (39.3% vs 1%), nausea/vomiting (39.3% vs 17.1%), kidney effects (8.7% vs 5.9%), second primary malignancies (2.1% vs 1%), and intracranial bleeding (1.3% vs 1.5%).

High-grade treatment-emergent AEs occurred in 52.7% of patients receiving LuPSMA compared with 38% of patients treated with SOC alone. The most common grade 3-5 AEs reported in the LuPSMA arm were bone marrow suppression (23.4% vs 6.8% in the control arm), fatigue (7% vs 2.4%, respectively), kidney effects (3.4% vs 2.9%), and nausea/vomiting (1.5% vs 0.5%).

Original article here > urologytimes.com/view/fda-g...

[addicted2cycling]

👍👍

[Hidden]

I wonder how many thousands of men have already benefited from this over the years.

[Hidden in reply to Hidden]

7342

[Vangogh1961]

All these studies for mcrpc. I wonder if it would be more effective prior to becoming resistant.

[MateoBeach in reply to Vangogh1961]

Yes. That has already been demonstrated in the countries and research where it has been used and is available for many years now. Germany, Australia, India, England and others. Many on this site who have the means have traveled abroad for these treatments while the FDA was ignoring all quality evidence outside of the USA. It will not be approved here anytime in the foreseeable future for hormone sensitive disease. Must take the matter into our own hands if we have HSPC and PSMA avid disease.

[Nirman in reply to MateoBeach]

Yes and even though if you have become castration resistant but haven’t performed any chemo then also good option to consider you’ll have better quality of life with very low side effects compared to chemo therapy however this is just my opinion and I can be wrong please everyone do your own research before decision making

[Vangogh1961]

I know. I work in healthcare and deal with insurances daily. Our healthcare sucks.

[Hidden]

So, best guess what this means for a timeframe of when people in this country could expect to get the LU 177 treatment?

[immunity1]

anecdoctal evidence, including my 6 treatments, suggests early treatment without bone metastasis works best.